home / stock / inmb / inmb news

INMB News and Press, INmune Bio Inc. From 04/25/24

Stock Information
Company Name: INmune Bio Inc.
Stock Symbol: INMB
Market: NYSE
Website: inmunebio.com
Menu
INMB INMB Quote INMB Short INMB News INMB Articles INMB Message Board
Get INMB Alerts

News, Short Squeeze, Breakout and More Instantly...
INMB - INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today t...
INMB - INmune Bio Inc. Announces 24-Month Stability Validation of XPro(TM) for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is delighted to announce the suc...

INMB - When the Price of (INMB) Talks, People Listen

2024-04-22 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

INMB - INmune Bio rises 2%, on $4.5M direct offering

2024-04-22 08:16:12 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) Seeking Alpha’s Quant Rating on INmune Bio Historical earnings data for INmune Bio Financial information for INmune Bio Read the full articl...
INMB - INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today t...

INMB - INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

2024-04-22 04:27:08 ET Summary INmune Bio is focused on developing drugs for neurology and cancer medicine. The company's most advanced product candidate is XPro 1595, which is being developed for Alzheimer's disease. INMB's financial situation may require a cash raise by the ...

INMB - INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage im...
INMB - Trading (INMB) With Integrated Risk Controls

2024-04-02 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

INMB - INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

2024-03-28 20:18:07 ET INmune Bio, Inc. (INMB) Q4 2023 Earnings Conference Call March 28, 2024, 04:30 PM ET Company Participants RJ Tesi - Chief Executive Officer David Moss - Chief Financial Officer Mark Lowdell - Chief Scientific Officer Conference Call P...

INMB - INmune Bio GAAP EPS of -$1.67 misses by $0.02, revenue of $0.15M beats by $0.01M

2024-03-28 16:06:23 ET More on INmune Bio INmune Bio: Caution Still Warranted But Upgrading To Hold Seeking Alpha’s Quant Rating on INmune Bio Historical earnings data for INmune Bio Financial information for INmune Bio Read the full article ...
Previous 10 Next 10